Stock BEAM BEAM THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/06/2024 BST 		5-day change 1st Jan Change
24.84 USD +2.43% Intraday chart for Beam Therapeutics Inc. +7.21% -8.74%
06-26 Beam Therapeutics Inc. Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency CI
06-14 Beam Therapeutics Inc. Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease CI

Evolution of the average Target Price on Beam Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

9b431c2abf2d417593e316ad20.-f58tRPpF65U3dE7bXcIW79jpMER9XvUEK4vxYjHx3M.wJsy1GKxeuZmsJtPGyZ_DYwKyod8ojasRupbjtz-9iOUn0nTWZ121ziY4Q~b7bb6e10b46f8c3621bf4edef32870d5

Analyst Recommendations on Beam Therapeutics Inc.

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing MT
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk MT
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating MT
JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38 MT
BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35 MT
Jefferies Downgrades Beam Therapeutics to Hold From Buy, Cuts Price Target to $30 From $75 MT
Cantor Fitzgerald Lowers Price Target on Beam Therapeutics to $32 From $56, Maintains Overweight Rating MT
Credit Suisse Adjusts Beam Therapeutics' Price Target to $47 From $46, Keeps Neutral Rating MT
Citigroup Adjusts Beam Therapeutics Price Target to $56 From $60, Maintains Buy Rating MT
RBC Cuts Beam Therapeutics' Price Target to $32 From $42, Keeps Sector Perform Speculative Risk Rating MT
Citigroup Adjusts Price Target on Beam Therapeutics to $60 From $62, Keeps Buy Rating MT
Barclays Adjusts Price Target on Beam Therapeutics to $41 From $45, Keeps Equalweight Rating MT
RBC Cuts Price Target on Beam Therapeutics to $42 From $50, Maintains Sector Perform, Speculative Risk Rating MT
Bernstein Initiates Beam Therapeutics at Market Perform With $37 Price Target MT
Wells Fargo Adjusts Price Target on Beam Therapeutics to $105 From $125, Keeps Overweight Rating MT
Cantor Fitzgerald Starts Beam Therapeutics at Overweight With $62 Price Target MT
SVB Securities Trims Price Target on Beam Therapeutics to $77 From $81, Maintains Outperform Rating MT
BMO Capital Upgrades Beam Therapeutics to Outperform From Market Perform, Raises Price Target to $66 From $61 MT
Citigroup Initiates Beam Therapeutics at Buy Rating With $62 Price Target MT
Credit Suisse Lowers Beam Therapeutics' Price Target to $53 From $65 to Reflect Delays to BEAM-102, Keeps Neutral Rating MT
Wedbush Adjusts Beam Therapeutics Price Target to $79 From $100, Maintains Outperform Rating MT
SVB Leerink Adjusts Price Target on Beam Therapeutics to $81 From $82, Maintains Outperform Rating MT
SVB Securities Adjusts Beam Therapeutics' Price Target to $113 from $118, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
24.84 USD
Average target price
48.38 USD
Spread / Average Target
+94.79%
High Price Target
78 USD
Spread / Highest target
+214.01%
Low Price Target
23 USD
Spread / Lowest Target
-7.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Beam Therapeutics Inc.

Barclays
RBC Capital Markets
Wedbush
JPMorgan Chase
BofA Securities
Jefferies & Co.
Cantor Fitzgerald
Credit Suisse
Citigroup
Bernstein
Wells Fargo Securities
SVB Securities LLC
BMO Capital
Guggenheim
SVB Leerink
Redburn
J.P. Morgan Chase

Ratings for Beam Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. Consensus Beam Therapeutics Inc.